Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel technology to monitor ’hidden depths’ of silent killer

02.10.2003


New studies, ASTEROID and ORION, combine CRESTOR™ with cutting-edge imaging techniques, to be at the forefront of the fight against atherosclerosis



Details of two new studies announced by AstraZeneca at the XIIIth International Symposium on Atherosclerosis (ISA) could provide the clearest picture yet of the effects of statins on atherosclerosis, the main cause of coronary artery disease.

Each study is combining the highly effective statin CRESTOR (rosuvastatin) with cutting-edge imaging technology: intravascular ultrasound (IVUS)1 or magnetic resonance imaging (MRI)2,3; to evaluate whether CRESTOR can slow the progression or even lead to a regression of atherosclerosis.


Atherosclerosis gradually narrows the blood vessels, which can lead to a reduction in blood supply to vital organs such as the brain and heart, in some cases this can lead to angina and even a stroke or heart attack. A number of studies have shown that statins may slow the progression or even cause regression of atherosclerosis.4-7 Lowering LDL-cholesterol (LDL-C) slows the progression of atherosclerosis, however, it has been suggested that a larger reduction of at least 40% in LDL-C is needed to observe a regression of atherosclerosis.8,9

Treatment of atherosclerosis should be considered an important target as clinical studies have shown that <1% regression of coronary atherosclerosis is associated with major (70-80%) reductions in clinical events such as heart attacks.10

"Patients with atherosclerosis can show no symptoms for years before experiencing a serious, sometimes fatal, cardiovascular event – often making this disease a silent killer," explained Professor Gunnar Olsson, Vice President and Head of Cardiovascular Therapy Area, AstraZeneca.

"We know that raised LDL-C (or bad cholesterol) and low levels of HDL-C (or good cholesterol) are major risk factors for atherosclerosis and coronary heart disease. CRESTOR can reduce LDL-cholesterol significantly more than the same and some higher doses of other widely used statins and also provides the added benefit of raising HDL-cholesterol or good cholesterol. The three ongoing studies, ASTEROID, ORION and METEOR will demonstrate the benefits of CRESTOR on the atherosclerotic disease process thereby offering the potential for improving the prognosis of patients with, or at risk of, cardiovascular disease – the world’s number one killer."

ASTEROID1 and ORION2, 3, 11 are the first studies to evaluate CRESTOR 40mg – which has been shown to reduce LDL-C by up to 63%12 – on atherosclerosis using the novel imaging technologies IVUS and MRI.

Dr. Steven Nissen, Medical Director of the Cardiovascular Coordinating Center at the Cleveland Clinic Foundation, USA, is the principal investigator on the ASTEROID study. He commented: "Current imaging technology, such as coronary angiography, has only allowed us to visualise the narrowing of the blood vessel caused by atherosclerosis. IVUS lets us see the equally dangerous atherosclerosis hidden within the vessel wall. We are visualising not just the tip of the iceberg, but also what is below the waterline. CRESTOR, compared to other statins, provides outstanding efficacy both in terms of reducing LDL-C (bad cholesterol) and raising HDL-C (good cholesterol). ASTEROID will determine if a maximum dose (40mg) of this particular agent can actually reduce the burden of coronary atherosclerosis during two years of treatment."

"By using non-invasive MRI in ORION we will be able to measure the exact shape, size and distribution of atherosclerosis in blood vessels which may enable us to better evaluate the vascular effects of lipid-lowering therapy, and in clinical practice the use of MRI could facilitate early diagnosis and treatment," stated Dr. Baocheng Chu of the University of Washington School of Medicine, Seattle and investigator for ORION. He continued, "ORION will also show the benefits of CRESTOR in hypercholesterolaemic patients with established atherosclerotic disease."

ASTEROID, which started in November 2002, will recruit 450 patients with coronary artery disease from approximately 60 centres worldwide who will be treated with CRESTOR 40mg once daily for 24 months. The study will measure the percentage change in coronary artery volume at the end of treatment using IVUS. Coronary atherosclerosis will also be assessed using quantitative coronary angiography. 1

ORION has completed recruitment and 39 hypercholesterolaemic patients with established atherosclerosis have been randomised to receive CRESTOR 5mg or 40mg for 24 months. Baseline measurements from patients enrolled in the study were announced at ISA. The change in bilateral carotid artery wall volume will be measured by using MRI. Changes in the intima media thickness of the carotid arteries will also be measured using B-mode ultrasound. 2, 3, 11

METEOR is the third study within the GALAXY Programme evaluating the effects of CRESTOR on atherosclerosis.13 The study which started in August 2002 is using B-mode ultrasound to compare the effects of CRESTOR 40mg or placebo on intima media thickness of the carotid arteries in 840 asymptomatic patients with sub-clinical atherosclerosis who are not routinely treated with statin medication.

CRESTOR has now received regulatory approvals across three continents; America, including the USA, Europe and Asia, and has been launched in several countries worldwide. CRESTOR is awaiting approval in a number of other countries over the coming months.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

AstraZeneca has more than 40 years experience in cardiovascular medicine and aims to increase lifespan and improve quality of life by reducing the risk, prevalence and impact of cardiovascular disease. AstraZeneca has a comprehensive cardiovascular portfolio including CRESTORTM, ATACANDTM, ZESTRILTM, TENORMINTM, SELOKEN ZOK /TOPROL-XLTM and PLENDILTM. This heritage is complemented by an innovative pipeline including the first oral direct thrombin inhibitor, EXANTATM, and a novel treatment for type 2 diabetes / metabolic syndrome, GALIDATM.



For further information please visit: http://www.AstraZenecaPressOffice.com.

Contact:
Julia Walker, Global PR Manager, Cardiovascular Therapy Area, AstraZeneca
Tel: 44-0-1625-510866
Mobile (in Japan): 81-0-90-5340-2294
Mobile: 44-0-7718-80-1984
Email: julia.walker@astrazeneca.com

Ellie Goss or Stephanie Martin, Shire Health International
Tel: 44-0-20-7471-1500
Ellie Goss’s mobile (in Japan): 81-0-90-5340-4799
Email: .goss@shirehealthinternational.com

Stephanie Martin | EurekAlert!
Further information:
http://www.tshg.com/
http://www.AstraZenecaPressOffice.com

More articles from Health and Medicine:

nachricht Usher syndrome: Gene therapy restores hearing and balance
25.09.2017 | Institut Pasteur

nachricht MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer
25.09.2017 | Case Western Reserve University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LaserTAB: More efficient and precise contacts thanks to human-robot collaboration

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Fraunhofer ISE Pushes World Record for Multicrystalline Silicon Solar Cells to 22.3 Percent

25.09.2017 | Power and Electrical Engineering

Usher syndrome: Gene therapy restores hearing and balance

25.09.2017 | Health and Medicine

An international team of physicists a coherent amplification effect in laser excited dielectrics

25.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>